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Background: Emerging technologies based on mass spectrometry or nuclear magnetic resonance enable the
monitoring of hundreds of small metabolites from tissues or body fluids. Profiling of metabolites can help elucidate
causal pathways linking established genetic variants to known disease risk factors such as blood lipid traits.
Methods: We applied statistical methodology to dissect causal relationships between single nucleotide
polymorphisms, metabolite concentrations, and serum lipid traits, focusing on 95 genetic loci reproducibly
associated with the four main serum lipids (total-, low-density lipoprotein-, and high-density lipoprotein- cholesterol
and triglycerides). The dataset used included 2,973 individuals from two independent population-based cohorts
with data for 151 small molecule metabolites and four main serum lipids. Three statistical approaches, namely
conditional analysis, Mendelian randomization, and structural equation modeling, were compared to investigate
causal relationship at sets of a single nucleotide polymorphism, a metabolite, and a lipid trait associated with
one another.
Results: A subset of three lipid-associated loci (FADS1, GCKR, and LPA) have a statistically significant association with
at least one main lipid and one metabolite concentration in our data, defining a total of 38 cross-associated sets of
a single nucleotide polymorphism, a metabolite and a lipid trait. Structural equation modeling provided sufficient
discrimination to indicate that the association of a single nucleotide polymorphism with a lipid trait was mediated
through a metabolite at 15 of the 38 sets, and involving variants at the FADS1 and GCKR loci.
Conclusions: These data provide a framework for evaluating the causal role of components of the metabolome (or
other intermediate factors) in mediating the association between established genetic variants and diseases or traits.Background
Recent technological advances allow for the collection of
high-dimensional molecular phenotype datasets in thou-
sands of individuals in a highly standardized manner. Meta-
bolomics technologies based on mass spectrometry (MS) or
nuclear magnetic resonance (NMR) enable the monitoring
of hundreds of small molecule metabolites in tissues or
body fluids [1-3]. Metabolites are intermediates in metabolic* Correspondence: ns6@sanger.ac.uk
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unless otherwise stated.pathways, which can be used to obtain a snapshot of the
physiological status of an individual at a given time point.
These datasets are typically organized into metabolic correl-
ation networks, which are mined to deduce unknown path-
ways from observed correlations, for instance to identify
metabolic signatures of disease status [4].
An emerging application of quantitative or semi-quantitative
technologies such as LC-MS-based metabolomics is
their combination with genome-wide association data to
discover genetic loci underlying variation in human me-
tabolism. Genome-wide metabolomics scans based on
hundreds of metabolite and lipid species measured usingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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over 100 independent loci for metabolites [5-14]. Import-
antly, several of the metabolite-associated loci correspond
to loci previously associated with risk of disease or their risk
factors such as Crohn’s disease, kidney disease, and serum
lipids. These first studies have demonstrated the usefulness
of large-scale metabolomics scans for formulating novel hy-
potheses on biochemical processes underpinning complex
traits and diseases. Once correlations between a metabolite
and a trait have been observed at a locus, however, the next
challenge is to tease apart causal relations from shared en-
vironmental effects or confounding.
This study explored the application of statistical infer-
ence to dissect causal relationships at complex-trait loci
where there is a concomitant association with one or more
metabolites. The analysis was focused on: (1) a set of SNPs
robustly associated with the four main circulating serum
lipids in genome-wide association studies at the time of
analysis, and including total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), and triglycerides (TG) [15,16]; (2)
151 metabolites measured using the Biocrates platform
[10]; and (3) the same four main serum lipids stated above.
Briefly, subsets of the SNPs that have statistically signifi-
cant associations with at least one metabolite and one lipid
in our data were selected. Conditional analysis, Mendelian
randomization (MR) [17], and structural equation model-
ing (SEM) [18-20] were then applied to the data to infer
statistically causal relationships in each of SNP-
metabolite-lipid sets previously defined.
The overarching aim of this study was to apply statistical
approaches to interrogate causal relationships using gen-
omic, metabolomic, and circulating lipid biomarker mea-
sures as an exemplar model. This provides a framework
that can be applied in many other settings both in relation




The Cooperative Health Research in the Region of Augsburg
(KORA) study is a series of independent population-
based epidemiological surveys and follow-up studies of
participants living in the region of Augsburg, Southern
Germany [21]. Blood samples for KORA F4 participants
were collected between 2006 and 2008 in a standardized
manner as previously described in detail [10].
Genotyping For genotyping, 1,814 KORA F4 samples
were randomly selected and genotyped using the Affy-
metrix Human SNP Array 6.0. After filtering out low call
rate SNPs and SNPs violating Hardy-Weinberg Equilib-
rium (HWE), imputation was conducted using IMPUTE
v0.4.2 [22] based on HapMap2.Lipid measurement Four serum lipid measurements (in
mg/dl) were collected using the Dimension RxL (Dade Beh-
ring); total cholesterol was determined by cholesterol-
esterase method (CHOL Flex, Dade-Behring, CHOD-PAP
method), HDL-C cholesterol by the AHDL Flex (Dade-Beh-
ring, CHOD-PAP method after selective release of HDL-C),
LDL-C cholesterol by the ALDL Flex (Dade Behring,
CHOD-PAP method after colourless usage of all non-LDL-
cholesterol) and triglycerides (TG) by the TGL Flex (Dade
Behring, enzymatic colorimetric test, GPO-PAP method).
Metabolite measurement A total of 3,044 KORA F4 sam-
ples were profiled using Biocrates AbsoluteIDQ Kit p150
across three periods of time (August/September 2008,
November/December 2008, and March/April 2009; which
were marked as three batches for the analysis). Finally,
a total of 1,797 KORA F4 samples were available with
genotypes, metabolite, and serum lipid measurements
(Additional file 1: Table S1).
Twins UK
The TwinsUK cohort is an adult twin British registry
recruited from the general population in the United
Kingdom [23]. Blood samples collection has been de-
scribed previously [9].
Genotyping TwinsUK samples were genotyped using a
combination of Illumina arrays (HumanHap300 [24,25],
HumanHap610Q, 1 M-Duo and 1.2MDuo 1 M). For each
dataset, the Illuminus calling algorithm [26] was used to as-
sign genotypes (posterior probability ≥0.95) and applied the
standardized data QC criteria based on: (1) call rate, hetero-
zygosity, ethnicity, and relatedness (for sample exclusion);
and (2) HWE, minor allele frequency, and call rate (for
SNPs). After pair-wise concordance check and further vis-
ual inspection, the genotype datasets from different arrays
were merged. Imputation was performed using the IM-
PUTE software package (v2) [22] using two reference
panels, P0 (HapMap2, rel 22, combined CEU+YRI +ASN
panels) and P1 (610 k+, including the combined Human-
Hap610 k and 1 M reduced to 610 k SNP content).
Lipid measurement Serum lipids for TwinsUK samples
were measured (in mmol/L) as described in [27] and the
LDL-C values were derived from HDL-C and TG values
using Friedewald’s equation. We converted all lipid mea-
surements to mg/dl values to be consistent with KORA,
by multiplying 38.67 for the LDL-C, HDL-C, and TC mea-
surements and 87.5 for the TG measurement.
Metabolite measurement Metabolite measurements were
performed using the metabolomics platform Biocrates
AbsoluteIDQ Kit p150 under an identical protocol as
for the KORA study at the Genome Analysis Center of
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selected TwinsUK samples with genotypes available, the
metabolite measurements were conducted in two batches:
one for 422 individuals in April 2009 and the other for
813 individuals in November 2009. One reference sample
was included in each of the 10 plates run in the second
batch, and metabolites were measured five times in each
plate. These reference measurements were used for quality
control purposes. After further QC (more details below), a
total of 1,176 TwinsUK samples were available with me-
tabolite, genotype, and serum-lipids measurements.
All the participants in both KORA and TwinsUK co-
horts have provided informed consent and this study has
been approved by Local Research Ethics Committee, Guy’s
and St. Thomas’ Hospital Ethics Committee for TwinsUK,
and Bayerische Landesärztekammer for KORA. Summary
information for all the samples can be found in Additional
file 1: Table S1.
Metabolomics measurements and QC
Metabolite panel
The analyzed metabolite panel comprises 163 differ-
ent metabolites, including 14 amino acids, hexoses
(H1), free carnitine (C0), 40 acylcarnitines (Cx:y), hydro-
xylacylcarnitines (C(OH)x:y), and dicarboxylacylcar-
nitines (Cx:y-DC), 15 sphingomyelins (SMx:y) and
N-hydroxylacyloylsphingosylphosphocholine (SM (OH)
x:y), 77 phosphatidylcholines (PC, aa = diacyl, ae = acyl-
alkyl), and 15 lyso-phosphatidylcholines. Quality pa-
rameters and quantification procedures were as de-
scribed by us [28]. After quality control, 151 different
metabolites remained in the dataset (Additional file 1:
Table S2). Lipid side-chain composition is abbreviated
as Cx:y, where x denotes the number of carbons in the
side chain and y the number of double bonds. For ex-
ample, ‘PC ae C32:1’ denotes an acyl-alkyl phosphatidyl-
choline with 32 carbons in the two fatty acid side
chains and a single double bond in one of them. Full
biochemical names are provided in Additional file 1:
Table S1. The precise position of the double bonds and
the distribution of the carbon atoms in different fatty acid
side chains cannot be determined with this technology.
In some cases, the mapping of metabolite names to indi-
vidual masses can be ambiguous. For example, stereo-
chemical differences are not always discernible, and
neither are isobaric fragments. In such cases, possible al-
ternative assignments are indicated.
Metabolite measurements in KORA and TwinsUK
Liquid handling of serum samples (10 μL) was per-
formed with a Hamilton Star (Hamilton Bonaduz AG)
robot, and samples were prepared for quantification
using the AbsoluteIDQ Kit p150 (BIOCRATES Life Sci-
ences AG). Sample analyses were done on 4000 Q TRAPLC/MS/MS System (AB Sciex) equipped with a Shimadzu
Prominence LC20AD pump and a SIL-20 AC autosam-
pler. The complete analytical process was performed using
the MetIQ software package, which is an integral part of
the AbsoluteIDQ kit. The MetIQ version 1.2.1r (Lithium),
released in April 2010 was used, which incorporates an
isotope correction. The experimental targeted metabolo-
mics measurement technique is described in detail by US
patent US 2007/0004044 [29] and in the manufacturer’s
manuals. A summary of the method can be found in else-
where [30-32], and a comprehensive overview of the field
and the related technologies is given in [33]. Briefly, a tar-
geted profiling scheme is used to quantitatively screen for
known small-molecule metabolites using multiple reaction
monitoring. Quantification of the metabolites of the bio-
logical sample is achieved by reference to appropriate in-
ternal standards. The method has been proven to conform
to 21CFR (Code of Federal Regulations) Part 11, which
implies proof of reproducibility within a given error range.
It has been applied in different academic and industrial
applications [11,33,34]. Concentrations of all analyzed me-
tabolites are reported in μM.
Batch effects
The mean differences of the metabolomics measurements
across different measurement batches were compared to
assess the influence of possible batch effects due to calibra-
tion of the machines at periodical time points. To account
for these differences in mean, a batch variable was included
in all analyses of metabolomics data. For consistency this
batch variable was applied to all metabolites independent
of demonstration of significant batch effects.
Quality control
Quality control of the metabolomics datasets was con-
ducted in two steps. In the first step the quality of all
metabolites was controlled by their coefficient of vari-
ation (CV) and missing value rate. For CV calculation,
one reference blood sample was measured five times on
each plate across all 10 plates. The CV for each metabol-
ite was calculated as follows:
CV ¼ sd all five reference measurementsð Þ
mean all five reference measurementsð Þ
The mean CV for each metabolite was computed from
all 10 plates. All metabolites with a mean CV greater than
25% were excluded. In addition to this criterion, a maximal
missing value rate of 5% was imposed. The second step of
our quality control was removing outlying data points and
outlying samples. This step was applied to log-transformed
metabolites, which were consistently closer to normality
than the untransformed metabolites based on the Anderson
Darling test. Outlying data points were defined as values
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For each sample, two outlying data points were claimed to
be independent if the correlation of corresponding metabo-
lites was less than 70%. Samples with more than three inde-
pendent outlying data points were excluded. For samples
with less than, or equal to, three independent outlying data
points, only the data points were excluded. Finally, all miss-
ing values were imputed using the R-package ‘mice’ [35],
which applies a linear regression approach to estimate a
distribution of each variable with missing values conditional
on all the other variables in the same multivariate dataset,
and replaces missing values with simulated values drawn
from this distribution.
Data summary
A total of 163 metabolites were measured in 3,061 sam-
ples of KORA F4 and in 1,237 samples of TwinsUK. In
the first step of quality control, 11 metabolites were ex-
cluded for having a CV higher than 25% and one metab-
olite for having more than 5% missing values (Additional
file 1: Table S2). In the second step, 17 samples were dis-
carded in KORA F4, due to their multiple independent
outlying data points and two samples in TwinsUK. In
addition, 419 and 254 outlying data points were treated
as missing values in KORA F4 and TwinsUK, respect-
ively. Together with the original missing data points,
0.09% of all data points were imputed in KORA F4 and
0.16% in the TwinsUK. After sample and metabolite ex-
clusions, a total of 151 metabolites were available for
analysis in 3,044 samples in KORA F4 and 1,235 samples
in TwinsUK (among which 1,797 samples in KORA F4
and 1,176 in TwinsUK had available metabolite, geno-
type, and serum-lipids measurements).
Candidate SNPs
The analysis focused on a total of 102 SNPs at 95 lipid-
associated loci reported as primary association signals in a
large-scale GWAS [16] for four lipid traits under the
genome-wide significance threshold (P value ≤5 × 10−8)
since our study would not have the same statistical power
to detect additional novel lipid-associated loci with even
smaller variances explained. Among the 102 SNPs, 52
were associated with TC, 37 with LDL-C, 47 with HDL-C,
and 32 with TG in the original study. Many of these loci
were associated with multiple lipid traits; for example, 41
were associated with two lipid traits, seven with three lipid
traits, and six with all four lipid traits. Summary informa-
tion for these SNPs measured in KORA and TwinsUK co-
horts can be found in Additional file 1: Table S3.
Statistical analyses
Metabolite and lipid trait transformation
The Anderson Darling test with and without log-
transformation was used to test deviation from normalityfor metabolite values. The log-transformed metabolites
were consistently closer to normality than the untrans-
formed metabolites, and thus all metabolite measurements
were log-transformed for analysis. The skewness of metab-
olites used in our causal analyses is reported in the
Additional file 1: Table S8. Most metabolites had skew-
ness between −0.5 and 0.5, indicating a symmetrical distri-
bution, with the exception of PC aa C32:2 in KORA
(skewness of −0.934) and five metabolites in TwinsUK.
However, these small deviations from symmetry had no
impact on the results and interpretation of causal relation-
ships (data not shown), so no filtering or transformation
were applied at this stage. For lipids, TG values were log-
transformed to achieve normality. The distribution of
LDL-C, HDL-C, and TC approximated normality and no
transformation was applied.
Heritability
For each metabolite, the narrow sense heritability was esti-
mated from 86 monozygotic and 245 dizygotic twin pairs
in TwinsUK under the ACE model. The ACE model as-
sumes that the phenotypic variance is influenced by addi-
tive genetic variation, common environmental effects, and
unique environmental effects (or random effects), and in-
fers the narrow sense heritability as the ratio of the esti-
mated additive genetic variance to the phenotypic variance.
The estimation was done by maximum likelihood methods
implemented in OpenMx software [36].
Spearman’s correlation tests
Spearman’s correlation tests were used to identify corre-
lated metabolite-lipid pairs, defined as P value <8.3 × 10−5
(Bonferroni corrected for 4 lipids and 151 metabolites)
and the same direction of Spearman’s rho in both cohorts.
We note that this correction over the number of tests may
be over-conservative owing to highly correlated metabolite
concentrations. Significant covariates (sex, age, and batch
effect) were regressed out from metabolites and lipids prior
to the correlation test. The computation of the P value and
Spearman’s rho were done using the function ‘cor.test’ in
R. Correlations were visualized by a heat map plot com-
bined with a hierarchical clustering using the ‘heatmap.2’
function of the R-package ‘gplots’ [37] with default settings.
Single-trait association and meta-analysis
The association of the 102 candidate SNPs with all 151
metabolites was investigated under the linear model
adjusting for age, batch, and sex, using SNPTEST and
MERLIN (with -fastassoc option) in the KORA and
TwinsUK sample, respectively. Summary statistics for
the two cohorts were combined based on the inverse of
the variance under the fixed effect meta-analysis model,
and SNPs with P value <3.3 × 10−6 (=0.05 / (102 × 151))
in the meta-analysis and nominal association (P <0.05)
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candidate SNPs and main lipids were also tested using
the same approach, and SNPs with P value <0.05 in the
TwinsUK-KORA meta-analysis were retained for analysis.
SNP-MET-LIP sets
Each metabolite with its statistically significantly associ-
ated SNP and lipid trait (defined by the criteria above)
was assigned to a unique SNP-MET-LIP dataset, where
SNP denotes a genetic variant, MET denotes a metabol-
ite, and LIP denotes a serum lipid trait. Only unrelated
samples in TwinsUK (N = 845) were included for ana-
lysis. For metabolites and lipid traits, covariates adjust-
ment were performed including age, sex, and batch
effect using a linear regression model [16].
Conditional analysis
For each SNP-MET-LIP set, the association between
SNP and LIP was tested under a linear regression model
with and without adjustment for MET.
Unadjusted model : yLIP ¼ αþ β⋅xSNP þ ε
Adjusted model for the metabolite : yLIP ¼ αadj þ
βadj⋅xSNP þ γadj⋅xMET þ εadj
To examine the influence of MET on SNP-LIP associ-
ation, the P value between SNP and LIP in adjusted model
was examined (in the way that P value ≥0.05 was considered
as unlikely to have direct association) and the change of the
estimated effect size of SNP was measured as follows.
Effect size change :¼ β^adj−β^
β^
Mendelian randomization
To estimate the causal effect of a metabolite on a lipid
trait, Mendelian randomization (MR) [17,38] was applied
to each SNP-MET-LIP set. Briefly in the MR approach, a
genetic variant (G, here SNP) is used as an instrumental
variable, which is not correlated with unknown con-
founders (U), to test a hypothesis that a variable (X, here
MET) is causal to the outcome (Y, here LIP).
X YG
U
MR studies rest on three assumptions: (1) G is associ-
ated with X; (2) G is independent of U; and (3) G is in-
dependent of Y given X and U, that is, there is only one
path from G to Y which is through X. For the estimationin MR, the Wald ratio, two-stage least squares and lim-
ited information maximum likelihood are commonly
used, which are equivalent for a single instrument [39].
The Wald ratio method was applied here to estimate the
unconfounded causal effect from MET to LIP [40] from
the ratio of the regression coefficient of SNP in a linear





The confidence interval of the unconfounded causal
effect was computed using 1,000 bootstrap replicates
[41] using the R-package ‘boot’.
Structural equation modeling
SEM represents a generalization of the MR model. While
MR tests the magnitude of an unconfounded effect under
a given hypothesis on a causal relationship (for example,
SNP→MET→ LIP), SEM measures the likelihood of each
of the possible hypotheses on path model implying a causal
relationship, to select the best fitted path model. When a
SNP and two traits are cross-associated with one another,
10 path models are suggested to be possible (Figure 1) [18].
Of these, only Models 4 to 10 were tested for SNP-MET-
LIP sets because Models 1 to 3 in Figure 1 were overpara-
meterized in our study (that is, they had zero degrees of
freedom). Models 1 to 3 are also Markov equivalent and
cannot be statistically distinguished as their maximized
likelihood are the same [42-44]. It should be also noted
that Model 4 in Figure 1 corresponds to the MR model,
however, the estimation of Model 4 within the SEM frame-
work would be done by the full information maximum
likelihood method, rather than by the limited information
maximum likelihood method that coincides with the MR
we used above. The former maximizes the full joint likeli-
hood and the latter the reduced likelihood only [39].
In details, the structural model can be denoted as
v ¼ Avþ u
where v is the vector of all the variables included in the
model, u is the vector of residuals, and A is the matrix of
the model coefficients. Under the same assumptions of a
simple regression model (including independence, con-
stant variance, and normality of the errors as well as lin-
earity between dependent and independent variables), the
expected covariance matrix Σ can be estimated as follows
Σ ¼ E vvT  ¼ I−Að Þ−1E uuT  I−Að Þ:
The matrix Σ = Σ(θ) is a function of model parameter
vector θ which includes model coefficients, measurement
errors, and structural disturbances. Next, the observed
Figure 1 SEM models. The figure shows all 10 possible path models for a cross-associated set of a SNP, a metabolite or ratio, and a serum lipid,
conditioned on the paths originating from the SNP [18]. Of these, only Models 4 to 10 were tested because Models 1 to 3 were overparameterized in
our study (that is, they had zero degrees of freedom). Models 1 to 3 are also Markov equivalent and cannot be statistically distinguished.
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riable values. Finally, the difference between expected
and observed covariance matrices Σ and S is evaluated
by Pearson’s chi-squared test (Goodness of Fit Test)
under the null hypothesis that the model fits the obser-
vation. The test statistic is derived as
ln Σ θð Þj j þ tr SΣ−1 θð Þ − ln Sj j−peX2
where p is the number of variables included. All SEM ana-
lyses were performed by using the R-package ‘sem’ [45].
Once the fit of all possible path models was evaluated,
the best fitted model was required to fit the following
four criteria as defined previously [46-48]: (1) Goodness
of Fit Test P value ≥0.05 (indicating how likely the hy-
pothesis is, or how well the observed data fit the expect-
ation of the model); (2) 0.9 < Goodness of Fit Index
(GoFI) ≤1; (3) Root Mean Squared Error Approximation
(RMSEA) ≤0.05; (4) smallest negative Bayesian Informa-
tion Criterion (BIC). Where multiple models fit to the
data, the best fitted model was selected if its BIC was at
least two units smaller than the next lowest BIC [48],
otherwise none was selected.
Software programs
Most analyses were carried out using publically available
packages in the R environment. SNP-metabolite associ-
ation analyses were carried out using SNPTEST and MER-
LIN. Heritability estimation was carried out in OpenMx.
Results
The study design is shown in Figure 2. The Biocrates
metabolomics profiling described in Illig et al. [10] wasextended to an additional 813 TwinsUK samples. After
stringent quality controls, a complete set of data for 151
metabolite concentrations (Additional file 1: Table S2)
and four main serum lipid traits (TC, LDL-C, HDL-C,
and TG) collected at the same time point became avail-
able for 1,797 and 1,176 individuals from the KORA
(Germany) and TwinsUK (UK) samples, respectively
(Additional file 1: Table S1).
To quantify the genetic basis of each metabolite con-
centration, the proportion of the heritable variance was
estimated from 86 monozygotic and 245 dizygotic twin
pairs in TwinsUK samples under the ACE model. A total
of 96 metabolites were observed to be moderately to
highly heritable (68 with 25% ≤ h2 < 50% and 28 with
h2 ≥ 50%) (Additional file 1: Table S2) confirming a
broad genetic basis for small metabolites.
Metabolite levels are associated with four main serum lipids
The Biocrates metabolite panel is particularly informative
for the study of lipid metabolism as it assays predomin-
antly lipid species including sphingolipids and glycero-
phospholipids, besides amino acids. Correlation between
metabolites and the four main serum lipid traits were
assessed using Spearman’s correlation test, showing that
all 151 metabolites were associated with at least one of
the four lipid traits, and 30 metabolites with all lipid
traits, at a stringent significance cutoff (P value <8.3 ×
10−5; Additional file 1: Table S4). In particular, 94 metab-
olites were statistically significantly associated with
TC, 84 with LDL-C, 71 with HDL-C, and 55 with TG
in both KORA and TwinsUK samples. A heat map plot
of metabolite-lipid correlation combined with a hierarch-
ical clustering highlights six main groups of metabolites
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Figure 2 Study design.
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Figure S1).
Metabolite levels are associated with known lipid SNPs
Genetic associations between 151 metabolites and 102
SNPs at 95 known lipid loci [16] were further tested.
Three loci, namely FADS1, GCKR, and LPA, were associ-
ated with at least one metabolite in the combined KORA
and TwinsUK dataset (P value <3.3 × 10−6, Table 1). SNP
rs174546 in FADS1 was statistically significantly associated
with concentrations of 34 different phosphatidylcholines
(among which the strongest association was observed at
PC aa C38:4 with Beta = −0.138 (SE = 0.007) and P value
= 6.22 × 10−83), rs1260326 in GCKR was associated with
the phosphatidylcholine PC aa C40:5 (Beta = 0.037 (0.008)
and P value = 1.26 × 10−6) and rs1564348 in LPA with car-
nitines C3 (Beta = 0.053 (0.011) and P value = 4.94 × 10−7)
and C8:1 (Beta = 0.09 (0.017) and P value = 6.28 × 10−8).
Among them, the phosphatidylcholine PC aa C40:5 was
associated with both rs174546 in FADS1 and rs1260326
in GCKR.
Metabolites mediate some lipid pathways
Based on the association result, all 38 significant SNP-
MET-LIP sets were selected (that is, where a metabolite
was statistically significantly associated with a SNP and a
lipid; Table 2). For each SNP-MET-LIP set, three differ-
ent statistical approaches were used to test the hypoth-
esis that MET might mediate SNP→ LIP pathway.
First, the SNP-LIP association was conditioned on MET
under a linear regression model in each SNP-MET-LIPset. A total of 19 metabolites associated with loci GCRK
and FADS1 resulted in marked declines of effect sizes
in the metabolite-adjusted model (Table 2 and Additional
file 1: Table S5). For example, the association between
rs1260326 in GCKR and TC showed a 66% decrease in
the effect size (from 3.274 mg/dl per copy of allele T,
P value = 0.00429 to 1.125 mg/dl, P value = 0.275) after
adjusting for PC aa C40:5. These observations were com-
patible with the hypothesis that these metabolites may
mediate the lipid pathways.
As a second approach, MR analysis was used to esti-
mate the unconfounded causal effect of a metabolite on
a lipid. For each SNP-MET-LIP set, the causal effect was
estimated by the Wald method and its confidence inter-
val was generated based on 1,000 bootstrap replicates. In
KORA, 17 SNP-MET-LIP sets showed a causal relation-
ship between MET and LIP (that is, MET→ LIP) at the
5% significance level, however, none of them were repli-
cated in TwinsUK at the same level of significance (al-
though two of them were significant at 10% significance
level and in need of further analysis in a larger dataset)
(Table 2 and Additional file 1: Table S6). For example,
by using rs174546 in FADS1 as an instrumental variable,
the unconfounded causal effect of PC ae C38:5 onto TG
was estimated to be −0.62 (95% CI = (−1.18, −0.05)) in
KORA, but only −0.53 (90% CI = (−1.02, −0.01)) in a set
of unrelated TwinsUK individuals (Figure 3).
Lastly, SEM was applied to test a broader range of
possible paths in each SNP-MET-LIP set. In a total of
15 SNP-MET-LIP sets, the best fitted model was shown
to be Model 4 (which corresponds to the path tested by
Table 1 Association summary statistics
Locus & SNP (effect/
other allele)
Metabolite Meta-analysis KORA TwinsUK
Beta (SE) P value Beta (SE) P value Beta (SE) P value
GCKR rs1260326 (T/C) PC aa C40:5 0.037 (0.008) 1.26 × 10−6 0.032 (0.009) 3.19 × 10−4 0.047 (0.014) 8.09 × 10−4
LPA rs1564348 (T/C) C3 0.053 (0.011) 4.94 × 10−7 0.049 (0.013) 1.15 × 10−4 0.062 (0.019) 1.24 × 10−3
C8:1 0.09 (0.017) 6.28 × 10−8 0.064 (0.02) 1.60 × 10−3 0.143 (0.029) 4.86 × 10−7
FADS1 rs174546 (T/C) PC aa C32:0 −0.038 (0.006) 3.69 × 10−10 −0.039 (0.007) 4.21 × 10−8 −0.036 (0.012) 1.70 × 10−3
PC aa C32:2 0.072 (0.012) 5.15 × 10−9 0.091 (0.017) 9.24 × 10−8 0.051 (0.018) 5.60 × 10−3
PC aa C34:2 0.038 (0.005) 2.03 × 10−13 0.037 (0.006) 2.13 × 10−10 0.044 (0.012) 1.82 × 10−4
PC aa C34:3 0.041 (0.008) 8.24 × 10−7 0.04 (0.01) 5.15 × 10−5 0.042 (0.015) 5.08 × 10−3
PC aa C34:4 −0.100 (0.01) 1.45 × 10−23 −0.106 (0.012) 3.24 × 10−17 −0.09 (0.017) 7.61 × 10−8
PC aa C36:2 0.043 (0.006) 6.32 × 10−14 0.045 (0.006) 3.75 × 10−12 0.034 (0.012) 4.01 × 10−3
PC aa C36:3 0.055 (0.006) 5.48 × 10−19 0.053 (0.007) 1.13 × 10−13 0.058 (0.012) 3.38 × 10−6
PC aa C36:4 −0.113 (0.006) 6.36 × 10−69 −0.112 (0.007) 1.21 × 10−48 −0.116 (0.013) 1.49 × 10−19
PC aa C36:5 −0.129 (0.012) 8.72 × 10−26 −0.143 (0.016) 8.29 × 10−20 −0.105 (0.02) 1.12 × 10−7
PC aa C36:6 −0.054 (0.011) 1.52 × 10−6 −0.051 (0.014) 2.34 × 10−4 −0.059 (0.019) 1.82 × 10−3
PC aa C38:4 −0.138 (0.007) 6.22 × 10−83 −0.136 (0.008) 5.47 × 10−56 −0.144 (0.014) 2.14 × 10−26
PC aa C38:5 −0.106 (0.007) 4.79 × 10−51 −0.108 (0.008) 4.48 × 10−36 −0.102 (0.013) 2.14 × 10−14
PC aa C40:4 −0.075 (0.008) 9.54 × 10−20 −0.075 (0.01) 6.79 × 10−14 −0.076 (0.015) 2.14 × 10−7
PC aa C40:5 −0.075 (0.008) 2.29 × 10−21 −0.075 (0.01) 8.02 × 10−15 −0.075 (0.014) 1.18 × 10−7
PC aa C40:6 −0.050 (0.009) 1.21 × 10−7 −0.045 (0.012) 9.55 × 10−5 −0.058 (0.016) 2.74 × 10−4
PC aa C42:0 −0.042 (0.009) 1.14 × 10−6 −0.035 (0.01) 7.54 × 10−4 −0.055 (0.015) 2.13 × 10−4
PC aa C42:1 −0.065 (0.008) 6.13 × 10−15 −0.062 (0.01) 4.31 × 10−10 −0.075 (0.016) 2.12 × 10−6
PC aa C42:4 −0.065 (0.007) 1.82 × 10−20 −0.064 (0.007) 1.15 × 10−17 −0.067 (0.02) 6.77 × 10−4
PC aa C42:6 −0.050 (0.007) 3.05 × 10−14 −0.05 (0.008) 2.70 × 10−10 −0.05 (0.012) 4.05 × 10−5
PC ae C36:2 0.060 (0.008) 1.58 × 10−15 0.07 (0.009) 5.04 × 10−15 0.034 (0.014) 1.41 × 10−2
PC ae C36:3 0.069 (0.007) 1.11 × 10−22 0.076 (0.008) 1.87 × 10−19 0.051 (0.013) 8.28 × 10−5
PC ae C36:4 −0.066 (0.007) 9.79 × 10−20 −0.058 (0.009) 2.46 × 10−11 −0.082 (0.013) 1.08 × 10−10
PC ae C36:5 −0.096 (0.008) 1.22 × 10−37 −0.088 (0.009) 1.09 × 10−22 −0.116 (0.014) 3.38 × 10−17
PC ae C38:4 −0.081 (0.006) 8.79 × 10−40 −0.076 (0.007) 5.96 × 10−26 −0.094 (0.012) 2.11 × 10−14
PC ae C38:5 −0.076 (0.006) 1.72 × 10−34 −0.071 (0.007) 1.30 × 10−21 −0.092 (0.012) 5.76 × 10−15
PC ae C38:6 −0.047 (0.007) 1.95 × 10−10 −0.041 (0.009) 2.91 × 10−6 −0.063 (0.014) 3.93 × 10−6
PC ae C40:1 −0.062 (0.008) 8.54 × 10−17 −0.067 (0.009) 1.85 × 10−14 −0.049 (0.015) 9.82 × 10−4
PC ae C40:4 −0.066 (0.006) 1.60 × 10−25 −0.064 (0.007) 3.23 × 10−20 −0.076 (0.016) 1.38 × 10−6
PC ae C40:5 −0.065 (0.006) 2.60 × 10−26 −0.063 (0.007) 1.38 × 10−19 −0.076 (0.014) 4.91 × 10−8
PC ae C40:6 −0.036 (0.008) 2.14 × 10−6 −0.029 (0.009) 9.86 × 10−4 −0.051 (0.014) 1.67 × 10−4
PC ae C42:1 −0.048 (0.008) 2.12 × 10−9 −0.047 (0.009) 7.56 × 10−8 −0.052 (0.02) 8.09 × 10−3
PC ae C42:5 −0.062 (0.006) 1.74 × 10−22 −0.057 (0.008) 4.97 × 10−14 −0.075 (0.012) 1.59 × 10−9
PC ae C44:5 −0.071 (0.008) 1.08 × 10−19 −0.066 (0.009) 2.49 × 10−12 −0.081 (0.014) 6.64 × 10−9
PC ae C44:6 −0.079 (0.008) 6.01 × 10−23 −0.075 (0.01) 3.47 × 10−14 −0.088 (0.014) 1.58 × 10−10
Summary statistics for the three loci selected for having a metabolite statistically significantly associated with a SNP and at least one lipid.
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KORA and TwinsUK. For example, in a set composed
of rs174546 in FADS1, PC ae C38:5 and TG, only
Model 4 showed Goodness of Fit Test P value ≥0.05 in
both cohorts (Figure 3). This set also satisfied other cri-
teria to be selected as the best fitted model; such asshowing 0.9 < GoFI ≤1, RMSEA ≤0.05 and smallest
negative BIC (Additional file 1: Table S7). Thus the
SEM analysis supports the model tested by MR that
phosphatidylcholines may mediate associations of GCKR
to TC and FADS to TG (Table 2 and Additional file 1:
Table S7).
Table 2 Results of conditional analysis, Mendelian randomization and structural equational modeling for the 38 significant SNP-MET-LIP sets
Conditional analysis Mendelian randomization Structural equation modeling
KORA TwinsUK KORA TwinsUK KORA TwinsUK
Locus SNP - MET - LIP Beta Beta Beta Beta Beta Beta 95% CI for Beta
(MET→ LIP using
SNP as an IV)
90% CI for Beta
(MET→ LIP using




model(LIP ~ SNP) (LIP ~ SNP +MET) Changes (LIP ~ SNP) (LIP ~ SNP +MET) Changes
GCKR rs1260326 - PC aa
C40:5 - TC




rs1260326 - PC aa
C40:5 - TG
0.081 0.054 −33% 0.075 0.058 −24% 0.28, 3.86 −0.38, 2.30 Model 8 (SNP→
LIP→MET)
LPA rs1564348 - C3 -
HDL-C
1.095 1.640 50% 0.248 1.171 372% −26.39, 46.60 −50.74, 35.81
rs1564348 - C8:1 -
HDL-C
1.095 1.328 21% 0.248 1.319 432% −24.00, 35.48 −16.69, 16.23
FADS1 rs174546 - PC aa
C32:0 - TG
0.043 0.061 43% 0.048 0.050 3% −2.02, 0.35 −2.45, 2.68 Model 10 (MET←
SNP→ LIP)
rs174546 - PC aa
C32:2 - TG




rs174546 - PC aa
C34:2 - TG




rs174546 - PC aa
C34:3 - TG




rs174546 - PC aa
C34:4 - TG
0.043 0.102 139% 0.048 0.076 58% −0.77, 0.04 −1.13, 0.44
rs174546 - PC aa
C36:2 - TG




rs174546 - PC aa
C36:3 - TG




rs174546 - PC aa
C36:4 - TG
0.043 0.157 268% 0.048 0.084 75% −0.72, −0.02 −0.83, 0.07
rs174546 - PC aa
C36:5 - TG
0.043 0.077 79% 0.048 0.054 13% −0.54, 0.03 −0.95, 0.12 Model 10 (MET←
SNP→ LIP)
rs174546 - PC aa
C36:6 - TG
0.043 0.060 40% 0.048 0.053 10% −1.52, 0.73 −1.92, 2.04
rs174546 - PC aa
C38:4 - TG
0.043 0.177 315% 0.048 0.097 102% −0.59, 0.01 −0.67, 0.06
rs174546 - PC aa
C38:5 - TG
0.043 0.131 206% 0.048 0.069 44% −0.74, −0.02 −0.96, 0.07
rs174546 - PC aa
C40:4 - TG
0.043 0.103 140% 0.048 0.076 58% −1.10, 0.13 −1.27, 0.44
rs174546 - PC aa
C40:5 - TG
0.043 0.115 168% 0.048 0.077 60% −1.07, 0.15 −1.22, 0.33
rs174546 - PC aa
C40:6 - TG

















Table 2 Results of conditional analysis, Mendelian randomization and structural equational modeling for the 38 significant SNP-MET-LIP sets (Continued)
rs174546 - PC aa
C42:0 - TG




rs174546 - PC aa
C42:1 - TG




rs174546 - PC aa
C42:4 - TG
0.043 0.054 26% 0.048 0.051 6% −1.29, 0.03 −1.20, 0.63 Model 10 (MET←
SNP→ LIP)
rs174546 - PC aa
C42:6 - TG
0.043 0.067 57% 0.048 0.048 0% −1.77, 0.33 −1.76, 0.48 Model 10 (MET←
SNP→ LIP)
rs174546 - PC ae
C36:2 - TG
0.043 0.058 36% 0.048 0.054 12% −0.06, 1.14 −3.89, 2.77
rs174546 - PC ae
C36:3 - TG
0.043 0.069 61% 0.048 0.062 29% −0.01, 1.03 −0.76, 1.89
rs174546 - PC ae
C36:4 - TG
0.043 0.044 2% 0.048 0.037 −23% −1.39, 0.11 −1.13, 0.10 Model 4 (SNP→
MET→ LIP)
rs174546 - PC ae
C36:5 - TG




rs174546 - PC ae
C38:4 - TG
0.043 0.036 −16% 0.048 0.044 −8% −1.10, −0.06 −1.01, 0.07 Model 10 (MET←
SNP→ LIP)
rs174546 - PC ae
C38:5 - TG




rs174546 - PC ae
C38:6 - TG
0.043 0.039 −10% 0.048 0.030 −37% −1.99, 0.18 −1.52, 0.13 Model 4 (SNP→
MET→ LIP)
rs174546 - PC ae
C40:1 - TG
0.043 0.056 30% 0.048 0.046 −3% −1.19, 0.10 −2.02, 1.04 Model 10 (MET←
SNP→ LIP)
rs174546 - PC ae
C40:4 - TG




rs174546 - PC ae
C40:5 - TG




rs174546 - PC ae
C40:6 - TG




rs174546 - PC ae
C42:1 - TG
0.043 0.060 41% 0.048 0.051 6% −1.81, 0.26 −1.74, 1.72 Model 10 (MET←
SNP→ LIP)
rs174546 - PC ae
C42:5 - TG




rs174546 - PC ae
C44:5 – TG




rs174546 - PC ae
C44:6 – TG




Effect size declines in conditional analysis, confidence intervals not containing 0 in Mendelian randomization, and Model 4 reported as the best fitted model in structural equation modeling in each cohort were

















Structural Equation Modeling (KORA)
Measure the model fit and select the best fitted 
path model among the models 4-10 in Figure2
rs174546 TG
Mendelian Randomization (KORA)
Measure the significance of  unconfounded effect 
from MET to LIP assuming MET LIP
rs174546 TG
Conditional Analysis (KORA)
Measure the effect size decreases from SNP to LIP 
after adjusting for MET
Beta decrease = 30% 





Structural Equation Modeling (TwinsUK)
Replication
Best fitted model = Model 4




95%CI = (-1.13, 0.12)




Beta decrease = 55% 
(0.048    0.022 after adjustment)
Beta = -0.62
95% CI = (-1.18,-0.05)
Best fitted model = Model 4
(Goodness of fit P = 0.13)
Figure 3 Three different statistical analyses to test the hypothesis that a metabolite mediates the FADS1→ TG pathway. The rs174546-T
allele in FADS1 locus is associated with both triglycerides and a small molecule metabolite, PC ae C38:5. We have tested the hypothesis that a
metabolite mediates the lipid pathway using three different statistical approaches. The conditional analysis (left) confirmed that the effect size of
rs174546 on triglyceride decreased conditional on PC ae C38:5 in both KORA and TwinsUK cohorts (top and bottom). The MR (middle) estimated
a statistically significant causal effect of PC ae C38:5 on triglyceride, which however was not replicated in TwinsUK at 5% significance level,
perhaps due to the small sample size (KORA = 1,797 and unrelated TwinsUK = 845). The SEM (right) showed that out of all possible models tested,
the model 4 (rs174546→ PC ae C38:5→ trycliceride) was the best fitted one in both cohorts.
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Blood lipid levels are major risk factors for coronary artery
disease (CAD) and myocardial infarction (MI), and targets
for therapeutic intervention. Recent large scale meta-
analyses of genome-wide association scans (GWAS) to-
taling >100,000 individuals has identified a total of 95
independent and common loci statistically significantly
associated with at least one of the four main lipid traits
(TC, LDL-C, HDL-C, and TG) [15,16]. Some of these loci
are mapped to genes that are well known therapeutic tar-
gets [49-51], but for the majority, little is known in terms
of their biological function or their value as therapeutic
targets. Further characterization of the pathways via which
these loci may influence lipid species is a necessary step
towards evaluating their therapeutic potential.
In this study, the potential roles of metabolites as inter-
mediate phenotypes of the four main lipid traits were ex-
amined. First, we showed that all 151 small metabolites
profiled on the Biocrates metabolite panel were statistically
significantly associated with lipid traits in two independent
cohorts. Second, we demonstrated that 37 of these metabo-
lites were robustly associated with variants at three different
lipid-associated loci, including one metabolite associated
with two loci, highlighting both known and potential new
biochemical correlates (summarized in Table 3). Third, we
applied a statistical framework composed of conditional
analysis, MR, and SEM to investigate the role of metabo-
lites in lipid pathways, and showed that one or more me-
tabolites potentially mediate the SNP-lipid association at
two loci, FADS1 and GCKR (both statistically significant by
SEM, and FADS1 suggestively by MR).Overlap of associations of a genomic locus with different
complex traits can be useful to derive novel hypotheses on
possible underlying pleiotropic or causal effects. For in-
stance, recent highly powered meta-analyses have systemat-
ically compared the association of type 2 diabetes loci
with correlated glycemic (fasting glucose, fasting insulin,
2-h glucose, HbA1C, and others) and metabolic traits
(BMI, lipids, and others) [24,25,64-66] in an attempt to
better characterize physiologic processes underlying asso-
ciations at these loci. A similar degree of overlap has been
characterized at serum lipid and coronary artery disease
loci [16]. While these efforts have provided first important
insights into pathophysiologic correlates at disease variants,
observed correlations at a locus may often reflect shared
environmental effects or confounding rather than causal re-
lations between traits. Distinguishing causality from correl-
ation in these contexts is essential to identify modifiable
causes of disease and to unearth new avenues for thera-
peutic intervention.
The advantage of using metabolites as intermediate phe-
notypes is that they are more proximal to genes and bio-
logical pathways than downstream phenotypes or clinical
endpoints [11], ensuring more statistical power to detect
genetic associations compared to more complex lipid
traits. Furthermore, analysis of metabolites provides the
opportunity to dissect complex metabolic pathways into
their components. We showed here that through appro-
priate statistical tools and prioritization strategies we can
begin to dissect causal relationships. Although our infer-
ences are limited by the lipid-focused content of the
Biocrates metabolomic panel and by the study power, it
Table 3 Summary of known evidence or hypothesis on the functional and biological role of metabolites for each of the
three lipid loci
Locus Metabolite class Functional and biological evidence
GCKR Phosphatidylcholine GCKR encodes a glucokinase regulatory protein that inhibits glucokinase in liver and pancreatic islet cells by
binding non-covalently to form an inactive complex with the enzyme. The locus has been shown to have a
pleiotropic effect on multiple cardio-metabolic phenotypes [15,24,52-56]. We postulate here that GCKR SNPs
affect TC through regulation of phosphatidylcholine metabolism, a hypothesis that needs to be validated in
experimental settings.
LPA Carnitine A connection between Lp(a) and carnitine has been shown before. Derosa et al. [57] observed a statistically
significantly decreased plasma Lp(a) concentration after L-carnitine intake of up to six month . Moreover, after
a coadministration of simvastatin and carnitine the reduction in Lp(a) was significanty greater than after
simvastatin medication alone [58].
FADS1 Phosphatidylcholine The FADS1-2-3 gene cluster encodes for fatty acid desaturase enzymes regulating the desaturation of fatty
acids by adding double bonds between carbons of the fatty acyl chain [59-61]. Whereas FADS1 modifies the
efficiency of the fatty acid delta-5 desaturase reaction, FADS2 modifies the fatty acid delta-6 desaturase reaction.
GWAS of polyunsaturated fatty acids have shown associations between different fatty acids and the FADS1-2-3
gene cluster [12]. Arachidonic acid, most likely a side chain of PC aa C36:4, is presumably involved in
atherosclerotic processes [62,63].
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other physiological context can be obtained by applying
similar approaches to broader metabolite panels and
larger study sizes.
Importantly, we demonstrate that our results are ro-
bust in two independent populations and recapitulate a
known biological process. For instance, the most plaus-
ible path model at FADS1 predicts that phosphatidylcho-
lines mediate the association between SNP rs174546 and
TG. FADS1 encodes a fatty acid desaturase regulating
the desaturation of fatty acids by the addition of a fourth
double bond between carbons of the fatty acyl chain
[59-61], a role compatible with the observation in this
study. This provides proof-of-principle evidence that these
approaches deliver robust and interpretable evidence. We
further discriminated path models connecting rs1260326
in GCKR to TC through phosphatidylcholines. GCKR
encodes a glucokinase regulatory protein that inhibits
glucokinase in liver and pancreatic islet cells by binding
non-covalently to form an inactive complex with the en-
zyme. The locus has been shown to have a pleiotropic effect
on multiple cardio-metabolic phenotypes [15,24,52-56].
We postulate here that GCKR SNP rs1260326 affects
TC through regulation of phosphatidylcholine metabol-
ism, a hypothesis that needs to be validated in experi-
mental settings.
Conditional analysis is a commonly used approach to
show dependencies between the variables of the unadjusted
model and the variable being adjusted for. However, the dif-
ferent results between unadjusted and adjusted models
might be due to reverse causation or confounding rather
than causation. One of the most widely applied causal infer-
ence approaches is MR. If the direction of the association is
previously known between two variables (for example, a
metabolite and a lipid in a SNP-MET-LIP set), MR can
measure the extent of the unconfounded causal relationship
using genetic variants as instrumental variables. However,in some –omics level studies, the direction of the associ-
ation among variables cannot be easily assumed. To over-
come this limitation of MR, we also applied SEM, which
evaluates each hypothesis based upon the directional rela-
tionship of variables by comparing it with all possible hy-
potheses and infers the most likely causal relationship. By
applying both SEM and MR to our dataset, we obtained
significant support for our hypothesis on the direction and
the degree of association in each SNP-MET-LIP set. Our
framework suggests the usefulness of combined statistical
methods as an exploratory tool to infer causal relationship
from high-dimensional molecular data.
Although our approach helps to infer causation statisti-
cally, it has limitations. In MR, the validation for all of the
assumptions is not always feasible, although its violation
could increase the bias [67]. MR also has relatively low
statistical power and may be affected by weak instrument
bias as only the small percentage of phenotypic variance is
explained by single (or often multiple) genotypes for most
complex traits. Using weak genetic instruments may cause
biases [68]. Furthermore, traditional MR is limited in only
testing specific sets of hypotheses. SEM provides a
hypothesis-free approach that is complementary to MR,
as it enumerates all possible models and infers causality
from the most likely model. However, it may mislead
causal inference in the presence of unknown confounders
[46] or measurement errors [69]. Finally, the use of BIC
scores to select the most likely model may represent a fur-
ther limitation of the model. A recent study showed that
the new causal model selection test (CMST test) outper-
forms BIC in terms of statistical precision, although it has
lower statistical power [20]. More generally, both MR
and SEM in our suggestive framework are designed to
detect only linear relationships and targeted on a small set
of variables, which were statistically significantly cross-
associated with one another (that is, SNP-MET-LIP set).
Thus, this framework cannot be readily applied to
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are linearly and non-linearly related.
Recent papers based on Gaussian graphical models or
Bayesian networks [42,43,70-72] take into account all the
observed variables of a dataset to infer direct correlation
or directional correlation. For example, the IDA method
(Intervention-calculus when the DAG is Absent) estimates
total causal effects from all the observed variables using
PC algorithm and intervention calculus [42]. Although
these approaches are still at risk of being misled by un-
known confounders and measurement errors, in contrast
to MR, adding more meaningful observed variables to the
model may help to robustly handle unaccounted-for fac-
tors or high correlations among variables. Our future
studies will include improving the statistical framework
shown here, to be more adequate for increasingly multiple
high-dimensional datasets (such as -omics datasets). On
another note, well-designed simulation studies would be
beneficial to understand and hopefully overcome the limi-
tations of each of causal methods introduced in this paper.Conclusions
Biological systems are clearly far more complex than rela-
tively simple sets of equations. However, new insights on
underlying biological processes can be obtained from the
analysis of data generated in a highly standardized manner
and the careful choice of model variables. We showed
that, with the use of appropriate statistical instruments,
we could dissect the contribution of metabolites assessed
through high-throughput molecular profiling to complex
biological pathways. The application of these methods to
loci identified in large-scale associations of genome-wide
SNP data will provide powerful tools for dissecting meta-
bolic pathways at a wide range of complex trait loci. Pre-
liminary studies exploring metabolic signatures associated
with hypertension [73,74], myocardial ischemia [75], and
others [76,77] will aid the dissection of genetic and envir-
onmental causes of cardio-metabolic disease. The applica-
tion of metabolomics profiling to samples from large
population cohorts, stratified by known risk factors or ex-
posures, may thus provide alternative and powerful de-
signs to test causal relationships while minimizing the
impact of clinical confounding variables [77], and new av-
enues to improve prediction of clinical outcomes.Additional files
Additional file 1: Table S1. Description of study samples. Table S2.
Characteristics of metabolites analyzed in this study. Table S3. SNP
quality metrics in KORA and TwinsUK. Table S4. Metabolite-lipid
correlation metrics. Table S5. Results of conditional analysis. Table S6.
Results of Mendelian randomization. Table S7. Results of structural
equation modeling. Table S8. Skewness of metabolites in 38 significant
SNP-MET-LIP sets tested.Additional file 2: Figure S1. Metabolite-lipid correlation heat maps.
Heat map plot of metabolite-lipid correlation combined with a
hierarchical clustering to show six main groups of metabolites showing
similar patterns of correlation with main lipids. The groups are separated
by the heavy black line in the heat map and labeled 1 to 6 from top to
bottom. The metabolites in each group can be found in the table below.
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